| Literature DB >> 35664981 |
H Stettler1, J M Crowther2, M Brandt3, A Boxshall4, B Lu5, R de Salvo1, S Laing3, N Hennighausen3, S Bielfeldt3, P Blenkiron5.
Abstract
Background: Topical moisturizing products are widely used to alleviate the problems associated with xerotic skin. Their use affects many properties of the stratum corneum (SC) in a complex and interrelated manner. The range of measurement techniques available to the researcher has increased in recent years. However, few studies have looked for correlations between the different techniques for assessing how aspects of xerotic skin change over time as a result of topical moisturizer usage.Entities:
Year: 2021 PMID: 35664981 PMCID: PMC9060006 DOI: 10.1002/ski2.21
Source DB: PubMed Journal: Skin Health Dis ISSN: 2690-442X
Differences from baseline for the treated and untreated (xerotic) sites for the measurements and assessments after 3 weeks of moisturizer usage (Columns A and B)
| Measurement/assessment | A) Treated site difference to baseline | B) Untreated site difference to baseline | C) Difference between treated and untreated |
|---|---|---|---|
| Corneometer® CM825, a.u. |
| −1.71 ± 5.53, |
|
| Epsilon™ E100, permittivity ε |
| −0.29 ± 1.30, |
|
| Visioscan® VC20plus, scaliness score | −0.77 ± 2.217, | −0.92 ± 1.76, | −0.18 ± 2.17, |
| Visual dry skin grading, scale 0‐4 |
| 0.0, |
|
| TEWL Tewameter® TM300, g[H2O]m−2h−1 |
| −1.1 ± 2.20, | −0.9 ± 2.80, |
| CRS, SC/SD thickness, µm |
| 0.29 ± 2.91, |
|
| CRS, lipid/Protein ratio, 4–10 µm average |
| −0.05 ± 0.18, |
|
| Lipbarvis®, lipid lamella length (LLL), nm/1000 nm2 |
| 8.01 ± 15.41, |
|
| Lipbarvis®, cholesterol, ng/133 mm2 |
| −0.31 ± 1.23, |
|
| Lipbarvis®, free fatty acids, ng/133 mm2 |
| −0.01 ± 1.33, |
|
| Lipbarvis®, ceramide EOS, ng/133 mm2 | −0.03 ± 1.37, | −0.50 ± 0.92, | 0.47 ± 1.10, |
| Lipbarvis®, ceramide NP, ng/133 mm2 | 0.07 ± 1.00, | −0.17 ± 0.63, | 0.25 ± 0.68, |
| Lipbarvis®, ceramide NH, ng/133 mm2 |
|
|
|
Note: Shown are the differences between the treated and untreated sites after 3 weeks of moisturizer usage (Column C). Data has been given to two decimal points where available. Statistical differences (paired t‐test) with significance <0.05 are shown in bold. Data except for the Visioscan® VC20plus originally shared in the work by Stettler et al.
Abbreviation: CRS, confocal Raman spectroscopy.
FIGURE 1Transmission electron microscopy (TEM) images the lipid lamella structure of (a) xerotic, and (b) treated skin, collected during the study for Lipbarvis® assessment
Correlation p values between the confocal Raman spectroscopy (CRS) measure of lipid/protein ratio and the Lipbarvis® lipid parameters
|
| CRS lipid/protein ratio | Lipid lamella length | Cholesterol level | Free fatty acid level | Ceramide EOS level | Ceramide NP level | Ceramide NH level |
|---|---|---|---|---|---|---|---|
| CRS lipid/protein ratio |
|
| 0.3106 | 0.5005 | 0.5502 | 0.1975 | |
| Lipid lamella length |
|
|
| 0.3468 | 0.2259 |
| |
| Cholesterol level |
|
|
| 0.7058 | 0.1949 | 0.6021 | |
| Free fatty acid level | 0.3106 |
|
| 0.3297 | 0.8259 | 0.7767 | |
| Ceramide EOS level | 0.5005 | 0.3468 | 0.7058 | 0.3297 | 0.3740 | 0.3879 | |
| Ceramide NP level | 0.5502 | 0.2259 | 0.1949 | 0.8259 | 0.3740 |
| |
| Ceramide NH level | 0.1975 |
| 0.6021 | 0.7767 | 0.3879 |
|
FIGURE 2Comparison between the length of the SC lipid lamellae and CRS derived lipid to protein ratio for the untreated (xerotic) and treated skin sites. CRS, confocal Raman spectroscopy; SC, stratum corneum
FIGURE 3The relationship between visual grading of dryness and (a) Corneometer®, (b) Epsilon™ and (c) Visioscan® Scaliness scores. Each letter above the data points (‘A’, ‘B’ or ‘C’) indicate the homogeneous groups at 95% significance (p < 0.05) for the different measurement techniques
FIGURE 4Correlation between Corneometer® and Epsilon™ scores, for both untreated (xerotic) and treated skin sites